Balamuthia mandrillaris

From WikiMD's WELLNESSPEDIA

Balamuthia mandrillaris is a free-living amoeba that is pathogenic and can cause serious infections in humans and animals. It was first identified in 1986 and is the causative agent of Balamuthia amoebic encephalitis (BAE), a rare and often fatal disease of the central nervous system.

Taxonomy[edit]

Balamuthia mandrillaris belongs to the Balamuthiidae family and the Balamuthia genus. It is the only species in its genus. The organism was named after William Balamuth, a distinguished parasitologist, and the mandrill baboon, from which it was first isolated.

Life Cycle[edit]

The life cycle of Balamuthia mandrillaris consists of two stages: the trophozoite stage and the cyst stage. In the trophozoite stage, the amoeba is active and feeds on bacteria and other food sources. In the cyst stage, the amoeba forms a protective wall around itself and becomes dormant.

Pathogenesis[edit]

Balamuthia mandrillaris can cause Balamuthia amoebic encephalitis (BAE), a severe and often fatal brain infection. The amoeba can enter the body through the nasal passages or through open wounds. Once inside the body, it can travel to the brain and cause severe damage.

Diagnosis and Treatment[edit]

Diagnosis of Balamuthia mandrillaris infection is challenging due to its rarity and the nonspecific symptoms it causes. It is often diagnosed post-mortem. Treatment typically involves a combination of several drugs, including antifungal medications, antibiotics, and antiprotozoal drugs. However, the effectiveness of these treatments is limited, and the mortality rate remains high.

Prevention[edit]

Prevention of Balamuthia mandrillaris infection involves avoiding contact with soil and dust, particularly for individuals with open wounds or who are immunocompromised.

See Also[edit]








Sponsored Health Resource

W8MD weight loss success

W8MD Weight Loss, Sleep & MedSpa

Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.

GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.

Book a W8MD appointment · View GLP-1 specials

Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.

Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.

Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.